Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting -

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Cancers | Gastrointestinal disorders
Summary
RCT (n=380) found proportion of patients with no chemotherapy-induced nausea was significantly greater with olanzapine vs. placebo in 1st 24 hours after chemotherapy [AC] (74% vs. 45%), from 25 to 120 hours AC (42% vs. 25%), and overall 120-hour period (37% vs. 22%).
UKMi comment
Patients were receiving highly emetogenic chemotherapy and both groups received the randomised treatment in combination with dexamethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist.
Related links: